^
    Back
    Association details:
    Biomarker:BRAF V600E + MSI-H
    Cancer:Small Intestinal Carcinoma
    Regimen: (oxaliplatin + capecitabine) (Avastin (bevacizumab) + capecitabine + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Springer
    Title:

    Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report

    Published date:
    08/18/2021
    Excerpt:
    The expression of KRAS wild type, BRAFV600E mutation, and MSI-high was detected in the cecum cancer using molecular pathological examination. She received chemotherapy with XELOX + BEV regimen (capecitabine + oxaliplatin + bevacizumab). After four administrations, a computed tomography scan showed reduction of distant metastases, which suggested partial response.
    DOI:
    https://doi.org/10.1186/s40792-021-01265-w